US 8,377,903 B2
CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS
Log In
Please sign up or log in to access the advanced features of
Ex Parte Enterprise.
or Log in

General

US 8,377,903 B2
CLADRIBINE REGIMEN FOR TREATING MULTIPLE SCLEROSIS
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Elizabeth C Kemmerer
Art Unit:
1649 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology
Agent:
Saliwanchik, Lloyd & Eisenschenk
Inventors:
Giampiero De Luca; Arnaud Ythier; Alain Munafo; Maria Lopez-Bresnahan
Assignee:
MERCK SERONO SA
Priority:
12/20/05
Filed:
04/23/10
Granted:
02/19/13
Expiration:
06/02/25
Abstract
The present invention is related to the use of Cladribine for the preparation of a pharmaceutical formulation for the treatment of multiple sclerosis, especially relapsing-remitting multiple sclerosis or early secondary progressive multiple sclerosis, wherein the preparation is to be the orally administered and wherein re-treatments are possible.
Cooperative Patent Classification (CPC)
A61A61K2300/00A61P25/00A61K

Analytics

Cases

Patent Assignments

Citations